{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T16:09:21Z","timestamp":1772467761278,"version":"3.50.1"},"reference-count":71,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2012,1,1]],"date-time":"2012-01-01T00:00:00Z","timestamp":1325376000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Journal of Supportive Oncology"],"published-print":{"date-parts":[[2012,1]]},"DOI":"10.1016\/j.suponc.2011.08.001","type":"journal-article","created":{"date-parts":[[2012,1,12]],"date-time":"2012-01-12T05:22:28Z","timestamp":1326345748000},"page":"14-24","source":"Crossref","is-referenced-by-count":40,"title":["Managing Side Effects of Tyrosine Kinase Inhibitor Therapy to Optimize Adherence in Patients with Chronic Myeloid Leukemia: The Role of the Midlevel Practitioner"],"prefix":"10.1016","volume":"10","author":[{"given":"Megan","family":"Cornelison","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elias J.","family":"Jabbour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary Alma","family":"Welch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.suponc.2011.08.001_bib1","first-page":"324","article-title":"The changing profile of Ph-positive chronic myeloid leukemia at presentation: possible impact of earlier diagnosis on survival","volume":"84","author":"Cervantes","year":"1999","journal-title":"Haematologica"},{"key":"10.1016\/j.suponc.2011.08.001_bib2","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S0749-2081(03)00007-X","article-title":"Diagnosis, treatment, and nursing care of patients with chronic leukemia","volume":"19","author":"Breed","year":"2003","journal-title":"Semin Oncol Nurs"},{"key":"10.1016\/j.suponc.2011.08.001_bib3","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.beha.2009.07.007","article-title":"Epidemiology of chronic myeloid leukaemia (CML)","volume":"22","author":"Rohrbacher","year":"2009","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.suponc.2011.08.001_bib4","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1038\/315758a0","article-title":"Structural organization of the bcr gene and its role in the Ph' translocation","volume":"315","author":"Heisterkamp","year":"1985","journal-title":"Nature"},{"key":"10.1016\/j.suponc.2011.08.001_bib5","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1634\/theoncologist.6-3-233","article-title":"STI571: targeting BCR-ABL as therapy for CML","volume":"6","author":"Mauro","year":"2001","journal-title":"Oncologist"},{"key":"10.1016\/j.suponc.2011.08.001_bib6","doi-asserted-by":"crossref","first-page":"6558","DOI":"10.1073\/pnas.84.18.6558","article-title":"In vitro transformation of immature hematopoietic cells by the P210 BCR\/ABL oncogene product of the Philadelphia chromosome","volume":"84","author":"McLaughlin","year":"1987","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.suponc.2011.08.001_bib7","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1182\/blood.V21.1.89.89","article-title":"Comparison of 6-mercaptopurine and busulfan in chronic granulocytic leukemia","volume":"21","author":"Huguley","year":"1963","journal-title":"Blood"},{"key":"10.1016\/j.suponc.2011.08.001_bib8","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1093\/jnci\/89.21.1616","article-title":"Interferon alfa versus chemotherapy for chronic myeloid leukemia: a meta-analysis of seven randomized trials: Chronic Myeloid Leukemia Trialists' Collaborative Group","volume":"89","year":"1997","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.suponc.2011.08.001_bib9","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1056\/NEJM198604243141701","article-title":"Hematologic remission and cytogenetic improvement induced by recombinant human interferon alpha A in chronic myelogenous leukemia","volume":"314","author":"Talpaz","year":"1986","journal-title":"N Engl J Med"},{"key":"10.1016\/j.suponc.2011.08.001_bib10","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1016\/S0140-6736(95)92596-1","article-title":"UK Medical Research Council randomised, multicentre trial of interferon-alpha n1 for chronic myeloid leukaemia: improved survival irrespective of cytogenetic response","volume":"345","author":"Allan","year":"1995","journal-title":"Lancet"},{"key":"10.1016\/j.suponc.2011.08.001_bib11","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1200\/JCO.2009.26.3087","article-title":"Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib","volume":"28","author":"Marin","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.suponc.2011.08.001_bib12","doi-asserted-by":"crossref","first-page":"5401","DOI":"10.1182\/blood-2008-12-196543","article-title":"Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study","volume":"113","author":"Noens","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.suponc.2011.08.001_bib13","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1056\/NEJMra050100","article-title":"Adherence to medication","volume":"353","author":"Osterberg","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.suponc.2011.08.001_bib14","doi-asserted-by":"crossref","DOI":"10.2471\/BLT.07.043802","article-title":"Anti-tuberculosis medication side-effects constitute major factor for poor adherence to tuberculosis treatment","volume":"86","author":"Awofeso","year":"2008","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.suponc.2011.08.001_bib15","doi-asserted-by":"crossref","first-page":"54S","DOI":"10.1378\/chest.130.1_suppl.54S","article-title":"Developing the ideal inhaled corticosteroid","volume":"130","author":"Cerasoli","year":"2006","journal-title":"Chest"},{"key":"10.1016\/j.suponc.2011.08.001_bib16","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/j.1524-6175.2007.08028.x","article-title":"What factors contribute to the inadequate control of elevated blood pressure?","volume":"10","author":"Elliott","year":"2008","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"10.1016\/j.suponc.2011.08.001_bib17","doi-asserted-by":"crossref","first-page":"689","DOI":"10.7326\/0003-4819-149-10-200811180-00003","article-title":"Adverse events with 4 months of rifampin therapy or 9 months of isoniazid therapy for latent tuberculosis infection: a randomized trial","volume":"149","author":"Menzies","year":"2008","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.suponc.2011.08.001_bib18","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1001\/archpedi.157.3.249","article-title":"Barriers to HAART adherence among human immunodeficiency virus-infected adolescents","volume":"157","author":"Murphy","year":"2003","journal-title":"Arch Pediatr Adolesc Med"},{"key":"10.1016\/j.suponc.2011.08.001_bib19","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/1742-6405-5-21","article-title":"Significant improvements in self-reported gastrointestinal tolerability, quality of life, patient satisfaction, and adherence with lopinavir\/ritonavir tablet formulation compared with soft gel capsules","volume":"5","author":"Schrader","year":"2008","journal-title":"AIDS Res Ther"},{"key":"10.1016\/j.suponc.2011.08.001_bib20","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/j.leukres.2010.10.017","article-title":"Exploring chronic myeloid leukemia patients' reasons for not adhering to the oral anticancer drug imatinib as prescribed","volume":"35","author":"Eliasson","year":"2010","journal-title":"Leuk Res"},{"key":"10.1016\/j.suponc.2011.08.001_bib21","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"348","author":"O'Brien","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.suponc.2011.08.001_bib22","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1182\/asheducation-2007.1.371","article-title":"Medical management of CML","author":"Shah","year":"2007","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.suponc.2011.08.001_bib23","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1182\/blood-2007-03-080689","article-title":"Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance","volume":"110","author":"Kantarjian","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.suponc.2011.08.001_bib24","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1182\/blood-2007-04-083196","article-title":"Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia","volume":"111","author":"le Coutre","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.suponc.2011.08.001_bib25","doi-asserted-by":"crossref","first-page":"5143","DOI":"10.1182\/blood-2006-11-056028","article-title":"Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial","volume":"109","author":"Kantarjian","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.suponc.2011.08.001_bib26","volume":"vol. 2010","year":"2004"},{"key":"10.1016\/j.suponc.2011.08.001_bib27","volume":"vol. 2010","year":"2010"},{"key":"10.1016\/j.suponc.2011.08.001_bib28","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1182\/blood.V114.22.1126.1126","article-title":"International Randomized Study of Interferon Vs STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib","volume":"114","author":"Deininger","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.suponc.2011.08.001_bib29","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","article-title":"Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia","volume":"362","author":"Saglio","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.suponc.2011.08.001_bib30","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1182\/blood.V116.21.207.207","article-title":"ENESTnd update: continued superiority of nilotinib versus imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP)","volume":"116","author":"Hughes","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.suponc.2011.08.001_bib31","doi-asserted-by":"crossref","first-page":"6511","DOI":"10.1200\/jco.2011.29.15_suppl.6511","article-title":"Comparison of nilotinib and imatinib in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): ENESTnd 24-month follow-up","volume":"29","author":"Larson","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.suponc.2011.08.001_bib32","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","article-title":"Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia","volume":"362","author":"Kantarjian","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.suponc.2011.08.001_bib33","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1182\/blood.V116.21.206.206","article-title":"Dasatinib versus imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) in the DASISION trial: 18-month follow-up","volume":"116","author":"Shah","year":"2010","journal-title":"Blood"},{"issue":"2 suppl","key":"10.1016\/j.suponc.2011.08.001_bib34","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.6004\/jnccn.2011.0125","article-title":"NCCN Task Force Report","volume":"9","author":"O'Brien","year":"2011","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.suponc.2011.08.001_bib35","doi-asserted-by":"crossref","first-page":"6133","DOI":"10.1200\/jco.2010.28.15_suppl.6133","article-title":"Symptom burden in chronic myeloid leukemia (CML)","volume":"28","author":"Williams","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.suponc.2011.08.001_bib36","series-title":"Sprycel\u00ae (dasatinib) prescribing information","year":"2010"},{"key":"10.1016\/j.suponc.2011.08.001_bib37","series-title":"Gleevec\u00ae (imatinib mesylate) prescribing information","year":"2008"},{"key":"10.1016\/j.suponc.2011.08.001_bib38","series-title":"Tasigna\u00ae (nilotinib) prescribing information","year":"2010"},{"key":"10.1016\/j.suponc.2011.08.001_bib39","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.suponc.2011.08.001_bib40","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1182\/blood.V116.21.2291.2291","article-title":"Cardiac safety profile of imatinib and nilotinib in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): results from ENESTnd","volume":"116","author":"Larson","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.suponc.2011.08.001_bib41","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1182\/blood.V114.22.1129.1129","article-title":"Update on imatinib-resistant chronic myeloid leukemia patients in chronic phase (CML-CP) on nilotinib therapy at 24 months: clinical response, safety, and long-term outcomes","volume":"114","author":"Kantarjian","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.suponc.2011.08.001_bib42","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1182\/blood-2002-05-1451","article-title":"Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia","volume":"101","author":"Kantarjian","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.suponc.2011.08.001_bib43","series-title":"National Comprehensive Cancer Network: Clinical Practice Guidelines in Oncology","year":"2011"},{"key":"10.1016\/j.suponc.2011.08.001_bib44","first-page":"2092","article-title":"The effect of dose increase of imatinib mesylate in patients with chronic or accelerated phase chronic myelogenous leukemia with inadequate hematologic or cytogenetic response to initial treatment","volume":"9","author":"Zonder","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.suponc.2011.08.001_bib45","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/clpt.2009.208","article-title":"Clinical pharmacokinetics of the BCR-ABL tyrosine kinase inhibitor nilotinib","volume":"87","author":"Tanaka","year":"2010","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.suponc.2011.08.001_bib46","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.beha.2009.06.001","article-title":"Management of drug toxicities in chronic myeloid leukaemia","volume":"22","author":"Mauro","year":"2009","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.suponc.2011.08.001_bib47","doi-asserted-by":"crossref","first-page":"3908","DOI":"10.1200\/JCO.2007.12.0329","article-title":"Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure","volume":"25","author":"Quintas-Cardama","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.suponc.2011.08.001_bib48","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/1756-8722-2-46","article-title":"The occurrence and management of fluid retention associated with TKI therapy in CML, with a focus on dasatinib","volume":"2","author":"Masiello","year":"2009","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.suponc.2011.08.001_bib49","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1038\/leu.2009.38","article-title":"Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia","volume":"23","author":"Hochhaus","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.suponc.2011.08.001_bib50","doi-asserted-by":"crossref","first-page":"908","DOI":"10.3324\/haematol.2009.013979","article-title":"High-dose imatinib improves cytogenetic and molecular remissions in patients with pretreated Philadelphia-positive, BCR-ABL-positive chronic phase chronic myeloid leukemia: first results from the randomized CELSG phase III CML 11 \u201dISTAHIT\u201d study","volume":"95","author":"Petzer","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.suponc.2011.08.001_bib51","doi-asserted-by":"crossref","first-page":"3428","DOI":"10.1182\/blood-2007-08-103499","article-title":"Results of high-dose imatinib mesylate in intermediate Sokal risk chronic myeloid leukemia patients in early chronic phase: a phase 2 trial of the GIMEMA CML Working Party","volume":"113","author":"Castagnetti","year":"2009","journal-title":"Blood"},{"issue":"3 suppl","key":"10.1016\/j.suponc.2011.08.001_bib52","doi-asserted-by":"crossref","first-page":"S110","DOI":"10.1097\/00005650-198903001-00010","article-title":"Assessing the effects of physician-patient interactions on the outcomes of chronic disease","volume":"27","author":"Kaplan","year":"1989","journal-title":"Med Care"},{"key":"10.1016\/j.suponc.2011.08.001_bib53","doi-asserted-by":"crossref","first-page":"e75","DOI":"10.1182\/blood-2010-07-294330","article-title":"Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib","volume":"117","author":"Haouala","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.suponc.2011.08.001_bib54","first-page":"37","article-title":"Nursing strategies for patients on oral chemotherapy","volume":"15","author":"Hollywood","year":"2001","journal-title":"Oncology (Williston Park)"},{"key":"10.1016\/j.suponc.2011.08.001_bib55","series-title":"Abstract presented at the American Society of Hematology Annual Meeting","article-title":"Weekend drug holiday of dasatinib in CML patients not tolerating standard dosing regimens","author":"La Rosee","year":"2009"},{"key":"10.1016\/j.suponc.2011.08.001_bib56","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1097\/00005650-200209000-00009","article-title":"Patient adherence and medical treatment outcomes: a meta-analysis","volume":"40","author":"DiMatteo","year":"2002","journal-title":"Med Care"},{"key":"10.1016\/j.suponc.2011.08.001_bib57","doi-asserted-by":"crossref","first-page":"56","DOI":"10.3322\/caac.20004","article-title":"Patient adherence and persistence with oral anticancer treatment","volume":"59","author":"Ruddy","year":"2009","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.suponc.2011.08.001_bib58","doi-asserted-by":"crossref","first-page":"e1000422","DOI":"10.1371\/journal.pmed.1000422","article-title":"A randomized controlled trial comparing the effects of counseling and alarm device on HAART adherence and virologic outcomes","volume":"8","author":"Chung","year":"2011","journal-title":"PLoS Med"},{"key":"10.1016\/j.suponc.2011.08.001_bib59","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD007768.pub2","article-title":"Consumer-oriented interventions for evidence-based prescribing and medicines use: an overview of systematic reviews","volume":"5","author":"Ryan","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.suponc.2011.08.001_bib60","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1182\/blood.V116.21.1514.1514","article-title":"A global retrospective and physician-based analysis of adherence to tyrosine kinase inhibitor (TKI) therapies for chronic myeloid leukemia (CML)","volume":"116","author":"Guilhot","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.suponc.2011.08.001_bib61","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1136\/qhc.9.4.200","article-title":"Evidence-based patient empowerment","volume":"9","author":"Wensing","year":"2000","journal-title":"Qual Health Care"},{"issue":"2 suppl","key":"10.1016\/j.suponc.2011.08.001_bib62","doi-asserted-by":"crossref","first-page":"S96","DOI":"10.1086\/313859","article-title":"Management of the adverse effects of antiretroviral therapy and medication adherence","volume":"30","author":"Max","year":"2000","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.suponc.2011.08.001_bib63","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1097\/00012272-200510000-00005","article-title":"Symptom management in HIV\/AIDS: advancing the conceptualization","volume":"28","author":"Spirig","year":"2005","journal-title":"ANS Adv Nurs Sci"},{"key":"10.1016\/j.suponc.2011.08.001_bib64","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1086\/322698","article-title":"Strategies for optimizing adherence to highly active antiretroviral therapy: lessons from research and clinical practice","volume":"33","author":"Stone","year":"2001","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.suponc.2011.08.001_bib65","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1182\/blood-2004-04-1335","article-title":"Discontinuation of imatinib therapy after achieving a molecular response","volume":"104","author":"Cortes","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.suponc.2011.08.001_bib66","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","article-title":"Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial","volume":"11","author":"Mahon","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.suponc.2011.08.001_bib67","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1182\/blood.V108.11.168.168","article-title":"A phase 1\/2 study of SKI-606, a dual inhibitor of Src and Abl kinases, in adult patients with Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia (CML) or acute lymphocytic leukemia (ALL) relapsed, refractory or intolerant of imatinib","volume":"108","author":"Cortes","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.suponc.2011.08.001_bib68","doi-asserted-by":"crossref","first-page":"3586","DOI":"10.1016\/j.bmcl.2009.04.136","article-title":"The discovery of the potent aurora inhibitor MK-0457 (VX-680)","volume":"19","author":"Bebbington","year":"2009","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.suponc.2011.08.001_bib69","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/978-3-642-01222-8_14","article-title":"Danusertib (formerly PHA-739358)\u2014a novel combined pan-Aurora kinases and third generation Bcr-Abl tyrosine kinase inhibitor","volume":"184","author":"Gontarewicz","year":"2010","journal-title":"Recent Results Cancer Res"},{"key":"10.1016\/j.suponc.2011.08.001_bib70","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1182\/blood.V116.21.210.210","article-title":"A phase 1 trial of oral ponatinib (AP24534) in patients with refractory chronic myelogenous leukemia (CML) and other hematologic malignancies: emerging safety and clinical response findings","volume":"116","author":"Cortes","year":"2010","journal-title":"Blood"},{"issue":"1 suppl","key":"10.1016\/j.suponc.2011.08.001_bib71","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.3816\/CLML.2010.s.001","article-title":"Clinical algorithms for the treatment of patients with chronic myeloid leukemia: the 2010 perspective","volume":"10","author":"Jabbour","year":"2010","journal-title":"Clin Lymphoma Myeloma Leuk"}],"container-title":["The Journal of Supportive Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1544679411001832?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1544679411001832?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,6,30]],"date-time":"2020-06-30T17:35:10Z","timestamp":1593538510000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1544679411001832"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,1]]},"references-count":71,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,1]]}},"alternative-id":["S1544679411001832"],"URL":"https:\/\/doi.org\/10.1016\/j.suponc.2011.08.001","relation":{},"ISSN":["1544-6794"],"issn-type":[{"value":"1544-6794","type":"print"}],"subject":[],"published":{"date-parts":[[2012,1]]}}}